Histone Deacetylase Inhibitors Market Size

Histone Deacetylase Inhibitors Market size is poised to reach USD 3 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of histone deacetylase inhibitors was USD 1.20 Billion. The reason behind the growth is impelled by the rising cases of cancer across the globe. HDAC inhibitors that allow acetylation equilibrium to be restored may be helpful in the treatment of cancer as they are similar to other anti-cancer medications, and are widely being used as a single agent or in combination with other chemotherapeutics in the treatment of tumors by promoting tumor cell death. By 2040, there will be more than 25 million new instances of cancer annually throughout the world.

The growing research & development activities for the development of advanced drugs are believed to fuel the growth of histone deacetylase inhibitors market. The creation of HDAC inhibitors has become a key tactic in the design of novel therapies that are being developed as a new, focused class of anticancer medications and several HDAC inhibitors (HDAC) have already been approved by the Food and Drug Administration (FDA) and are now being tested in clinical settings for a variety of cancers.